Sign up
Pharma Capital

Bod Australia’s shares rise as it prepares to launch cannabis-based cosmetics

Planning to commercialise and distribute the products to consumers by 2018.
cannabis plant
Partnership with Swiss herbal extracts company

Bod Australia Ltd (ASX:BDA) has commenced exploratory formulation work on a new range of cannabis-based cosmetic products via its partnership with Swiss herbal extracts company Linnea SA.

Bod’s share prices has increased 70% in the past one week and is trading at $0.17 intra-day.

Pursuant to the agreement, Linnea will also assist Bod in developing cannabis-based topical treatments for inflammation and sensitive skin, including serums, foam-based creams and balms.

A key value-driver for the new cosmetic range will be the use of Linnea’s unique NioSkin™ ingredient as an active ingredient and transporter of the cannabis.

NioSkin provides superior therapeutic outcomes than standard cannabis cosmetics by efficiently enhancing skin penetration of the cannabis-based extracts.

Bod is currently conducting research and development for its cannabis-based skincare products and is planning to commercialise and distribute the products to consumers by 2018.

The products will be developed and manufactured at facilities in Italy, and exported to numerous major markets beyond Australia, including Asia and the Americas.

Discussions are underway with third-parties for white labelling and wholesale distribution.

The global skincare market is expected to reach $233.7 billion by 2022.



Register here to be notified of future BDA Company articles
View full BDA profile

Bod Australia Ltd Timeline

View All

Related Articles

Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.